Lightengale

After experiencing firsthand the challenges of delivering infusion therapy in the neonatal intensive care setting, Hans Utz founded Lightengale in 2018 to develop lighted intravenous tubing that reduces errors in high-acuity environments. He launched the company with a simple napkin sketch and a prototype made from light cables taped together in his basement. 

Lightengale engaged EGC in 2019 to support preparation of a successful NIH Phase I STTR award, which funded the transition from early prototype to a validated device for use in neonatal ICUs. The company subsequently partnered with EGC to secure another NSF STTR award to adapt the technology for use with extended IV tubing in hospital isolation settings during the COVID-19 pandemic. 

Following this initial momentum, the company has received support from the FDA Pediatric Device Consortium and was granted designation under the FDA’s Safer Technologies Program (STeP). These milestones have supported continued development of Lightengale’s intravenous tubing system as it advances toward clinical use. 

EGC is proud to have been part of Lightengale’s journey from its earliest stages—providing both scientific and accounting expertise to help the company succeed and thrive as it secures and manages the funding needed to bring its innovation to the world.